• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to secondary sidebar

OINDPnews


H&T Presspart Low GWP Banner
  • Home
  • News
    • Business
    • Features
    • Medical
    • Regulatory
    • Products and Services
    • People
  • Events
  • Suppliers
    • Supplier listing and advertising options
    • Capsules and blisters
    • Consultants
    • Contract research
    • Contract manufacturing
    • Devices
    • Education
    • Excipients
      • Clinical Technology
    • Filling equipment
    • Instruments
    • Particle manufacturing
    • Software and modeling
  • Jobs
  • Resources
    • Webinars
    • White papers
  • LGWP Propellants
    • HFA 152a
    • HFO-1234ze(E)
    • LGWP Regulation
  • Contact

Business

Adapt Pharma to develop Lightlake’s intranasal naloxone for opioid overdose reversal

Lightlake Therapeutics has agreed to license its intranasal naloxone for opioid overdose reversal to Adapt Pharma for possible development and sales milestones of more than $55 million, plus royalties, the company said. Lightlake recently announced that it started a new trial of the product with funding from the National Institute on Drug Abuse (NIDA). According to … [Read more...] about Adapt Pharma to develop Lightlake’s intranasal naloxone for opioid overdose reversal

GSK to change color of Relvar Ellipta

GSK has announced that it will change the color of the Relvar Ellipta fluticasone/vilanterol DPI starting in January 2015. The company said that it will remove the color blue from the inhaler and its packaging and will change the mouthpiece cover and packaging to yellow. Pharmacists had expressed concerns that patients would be confused because the color blue has been … [Read more...] about GSK to change color of Relvar Ellipta

Shire gets $15 million from CFFT for development of aerosolized mRNA therapy

Cystic Fibrosis Foundation Therapeutics (CFFT), a nonprofit associated with the Cystic Fibrosis Foundation, has announced that it will provide Shire with up to $15 million for development of an aerosol messenger RNA therapy designed to produce working CFTR protein in the lungs of CF patients. Gene mutations in CF patients disrupt normal CFTR protein production, … [Read more...] about Shire gets $15 million from CFFT for development of aerosolized mRNA therapy

Pfizer launches Ultibro Breezhaler in the UK

Pfizer has launched Novartis’ Ultibro Breezhaler indacaterol/glycopyrronium DPI for the treatment of COPD in the UK, the company said. Ultibro Breezhaler was approved in Europe in September 2013. In September 2014, Pfizer announced that it had entered into an agreement with Novartis to market both Ultibro Breezhaler and the Seebri Breezhaler glycopyrronium DPI in … [Read more...] about Pfizer launches Ultibro Breezhaler in the UK

Meda and Cipla sue Apotex over Dymista patents

Meda Pharmaceuticals and Cipla have filed suit against Apotex in the Delaware Federal District Court, claiming that Apotex's submission of an ANDA for a generic version of Dymista azelastine HCl/fluticasone propionate nasal spray violates patents related to Dymista that will not expire until 2026. Meda holds the licenses to US patents 8,163,723 and 8,168,620 … [Read more...] about Meda and Cipla sue Apotex over Dymista patents

Otsuka Pharmaceuticals to acquire Avanir

Avanir Pharmaceuticals, which just received a complete response letter from the FDA for its AVP-825 intranasal sumatriptan powder, has announced that it will be acquired by Otsuka Pharmaceutical for approximately $3.5 billion. Avanir will become an independent subsidiary of Otsuka America. Otsuka Pharmaceutical President and Representative Director Taro Iwamoto … [Read more...] about Otsuka Pharmaceuticals to acquire Avanir

Skyepharma announces launches in Spain, Italy, and Japan

Skyepharma has announced that Mundipharma has launched the Flutiform fluticasone/formoterol MDI for the treatment of asthma in Spain, triggering a milestone payment of €2.0 million. In addition, Mundipharma marketing partner Zambon Italia has now launched the same product in Italy under the brand name Abriff. Mundipharma Italy has been marketing the inhaler as … [Read more...] about Skyepharma announces launches in Spain, Italy, and Japan

Endo acquires rights to Trimel’s intranasal testosterone

Endo International has acquired exclusive US and Mexican rights to Trimel BioPharma's Natesto testosterone nasal gel, which was approved by the the FDA in May 2014 as a replacement treatment for men with low levels of endogenous testosterone. Endo is paying $25 million up front plus potential milestone payments. In addition, Endo will manufacture and supply the … [Read more...] about Endo acquires rights to Trimel’s intranasal testosterone

GSK Australia to add Ventolin nebules production capacity

GSK Australia has announced that it plans to invest AUD31 million in blow-fill-seal equipment for the manufacture of Venolin salbutamol nebules at its facility in Boronia, a suburb of Melbourne. The company cited increasing demand for asthma treatments from Turkey, Brazil, and China as the reason for the retrofit. The Boronia site is GSK's largest liquid product … [Read more...] about GSK Australia to add Ventolin nebules production capacity

Aegis Therapeutics gets patent for intranasal CNS drug delivery

The US Patent and Trademark Office (USPTO) has awarded US Patent No 8,883,728, "Intranasal administration of active agents to the central nervous system," to Aegis Therapeutics, the company said. The patent covers, "Pharmaceutical compositions and methods for delivering a polypeptide to the central nervous system of a mammal via intranasal administration are … [Read more...] about Aegis Therapeutics gets patent for intranasal CNS drug delivery

  • « Previous Page
  • Page 1
  • Interim pages omitted …
  • Page 99
  • Page 100
  • Page 101
  • Page 102
  • Page 103
  • Interim pages omitted …
  • Page 152
  • Next Page »

Primary Sidebar

Sign up for our free weekly newsletter

Upcoming Events
Sponsored by Intertek

Want information about upcoming OINDP-related events delivered directly to your inbox? click here

  • June 17-June 18: Rescon Europe 2025, Paris, France
  • June 19-June 20: Metered Dose Inhaler (MDI) Technology Training Course, online
  • June 22-June 25: ISAM Congress 2025, Washington, DC, USA
  • June 25-June 25: SMI.London 2025, London, UK
  • September 18-September 19: IPAC-RS Nasal Innovation Forum, West Trenton, NJ, USA
  • See all upcoming events

    Secondary Sidebar

    Suppliers

    Capsules and blisters
    Consultants
    Contract research
    Contract manufacturing
    Devices
    Education
    Excipients
    Filling equipment
    Instruments
    Particle manufacturing
    Software and modeling
    Proveris_180x150a
    Bespak Leading the Green Transition banner
    © 2025 OINDPnews